ATE473003T1 - Tacrolimus enthaltende feste dispersionen - Google Patents

Tacrolimus enthaltende feste dispersionen

Info

Publication number
ATE473003T1
ATE473003T1 AT04762795T AT04762795T ATE473003T1 AT E473003 T1 ATE473003 T1 AT E473003T1 AT 04762795 T AT04762795 T AT 04762795T AT 04762795 T AT04762795 T AT 04762795T AT E473003 T1 ATE473003 T1 AT E473003T1
Authority
AT
Austria
Prior art keywords
solid dispersions
dispersions containing
containing tacrolimus
tacrolimus
solid
Prior art date
Application number
AT04762795T
Other languages
English (en)
Inventor
Per Holm
Tomas Norling
Original Assignee
Lifecycle Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifecycle Pharma As filed Critical Lifecycle Pharma As
Application granted granted Critical
Publication of ATE473003T1 publication Critical patent/ATE473003T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT04762795T 2003-08-29 2004-08-30 Tacrolimus enthaltende feste dispersionen ATE473003T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200301232 2003-08-29
DKPA200301837 2003-12-11
US52979303P 2003-12-15 2003-12-15
DKPA200400079 2004-01-21
DKPA200400463 2004-03-23
DKPA200400467 2004-03-23
PCT/DK2004/000574 WO2005020994A1 (en) 2003-08-29 2004-08-30 Solid dispersions comprising tacrolimus

Publications (1)

Publication Number Publication Date
ATE473003T1 true ATE473003T1 (de) 2010-07-15

Family

ID=34280179

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04762795T ATE473003T1 (de) 2003-08-29 2004-08-30 Tacrolimus enthaltende feste dispersionen

Country Status (11)

Country Link
US (15) US7994214B2 (de)
EP (2) EP1663216B1 (de)
JP (2) JP4996249B2 (de)
AT (1) ATE473003T1 (de)
AU (2) AU2004267910B2 (de)
BR (2) BRPI0413927B8 (de)
CA (2) CA2537041C (de)
DE (1) DE602004028023D1 (de)
NO (2) NO334986B1 (de)
PL (2) PL1663217T3 (de)
WO (2) WO2005020993A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005004848A1 (en) * 2003-07-09 2005-01-20 Chong Kun Dang Pharmaceutical Corp. The solid dispersion of tacrolimus
BRPI0413927B8 (pt) 2003-08-29 2021-05-25 Lifecycle Pharma As composição farmacêutica compreendendo tacrolimus, forma de dosagem, uso da composição, e, método para a preparação da composição
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
CN101175481A (zh) * 2005-03-17 2008-05-07 伊兰制药国际有限公司 纳米颗粒免疫抑制化合物的可注射的组合物
WO2006136175A2 (en) * 2005-06-22 2006-12-28 Lifecycle Pharma A/S Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
EP1942887A1 (de) * 2005-10-07 2008-07-16 LifeCycle Pharma A/S Tacrolimus-kombinationsprodukte
FR2894143B1 (fr) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
US20080031949A1 (en) * 2006-07-24 2008-02-07 Cima Labs Inc. High dose orally dissolvable/disintegrable lyophilized dosage form
WO2008041553A1 (en) * 2006-09-26 2008-04-10 Astellas Pharma Inc. Tacrolimus sustained-release preparation
US20090011018A1 (en) * 2006-12-28 2009-01-08 Astellas Pharma Inc., Sustained release formulation for tacrolimus
UA93148C2 (ru) * 2007-03-29 2011-01-10 Панасэа Биотэк Лимитэд Дозированная форма тароликмуса модифицированного высвобождения
PT2079456E (pt) 2007-04-04 2013-03-13 Sigmoid Pharma Ltd Composições farmacêuticas de ciclosporina
ITMI20070720A1 (it) * 2007-04-06 2008-10-07 Monteresearch Srl Composizioni orali contenenti tacrolimus in forma amorfa
JP5139515B2 (ja) * 2007-04-25 2013-02-06 テバ ファーマシューティカル インダストリーズ リミティド 医薬賦形剤複合体
WO2008132707A1 (en) 2007-04-26 2008-11-06 Sigmoid Pharma Limited Manufacture of multiple minicapsules
WO2008132710A2 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
ES2634153T3 (es) * 2007-05-30 2017-09-26 Veloxis Pharmaceuticals A/S Forma de dosificación oral de una vez al día que comprende tacrolimus
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
CA2689978A1 (en) 2007-06-08 2008-12-18 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
TW200932240A (en) * 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
WO2009080030A1 (en) * 2007-12-21 2009-07-02 Lifecycle Pharma A/S Treatment of autoimmune hepatitis with a once daily oral dosage form comprising tacrolimus
CL2008000374A1 (es) 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
US12403095B2 (en) * 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
CA2729948C (en) * 2008-07-08 2021-11-23 Lifecycle Pharma A/S Tacrolimus for improved treatment of transplant patients
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2344183B1 (de) * 2008-10-10 2015-02-25 Alvine Pharmaceuticals, Inc. Darreichungsformen zur raschen aktivierung von zymogen
US9775802B2 (en) 2009-03-24 2017-10-03 Bausch & Lomb Incorporated Method for preparing suspensions of low-solubility materials
SMT201700555T1 (it) 2009-05-18 2018-01-11 Sigmoid Pharma Ltd Composizione comprendente gocce oleose
BR112012002963A2 (pt) 2009-08-12 2017-10-24 Sigmoid Pharma Ltd composições imunomoduladoras compreendendo uma matriz de polímero e uma fase oleosa
WO2011100975A2 (en) * 2010-02-17 2011-08-25 Lifecycle Pharma A/S Stabilized tacrolimus composition
WO2011122524A1 (ja) 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CA2819130A1 (en) * 2010-12-07 2012-06-14 The Johns Hopkins University Compositions and methods for mobilizing stem cells
KR20130028824A (ko) * 2011-09-09 2013-03-20 주식회사 삼양바이오팜 타크로리무스를 포함하는 고체 분산체 및 이의 제조방법
RU2635466C2 (ru) * 2012-04-08 2017-11-13 Теракоат Лтд Препараты термообратимого гидрогеля для применения при лечении нарушений уротелия
US9078925B2 (en) * 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CA2878689A1 (en) * 2012-07-12 2014-01-16 Abbvie Inc. Crystalline forms of an hcv inhibitor
WO2014078435A1 (en) 2012-11-14 2014-05-22 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide
EP4091609A1 (de) 2013-04-29 2022-11-23 Medregen, LLC Wundheilung durch mobilisierung von autologen stammzellen
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HRP20210150T1 (hr) 2014-11-07 2021-04-02 Sublimity Therapeutics Limited Pripravci koji sadrže ciklosporin
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
EP4066822A1 (de) * 2015-08-19 2022-10-05 Vivus, Inc. Pharmazeutische formulierungen
GB201600376D0 (en) 2016-01-08 2016-02-24 Chronos Therapeutics Ltd Novel therapeutic agents
US10618547B2 (en) * 2017-09-26 2020-04-14 Steering Solutions Ip Holding Corporation Regenerative current limiting of DC machines
US12036214B2 (en) 2018-07-13 2024-07-16 Council Of Scientific And Industrial Research [In/In] Solid dispersion comprising an anticancer compound for improved solubility and efficacy
MX2021002515A (es) * 2018-09-07 2021-04-28 Scherer Technologies Llc R P Estabilizacion de forma de dosis a base de lipidos solidos o semisolidos a traves de curar y adicionar surfactantes de bajo hlb.
CN113660934A (zh) 2018-11-21 2021-11-16 特默罗制药股份有限公司 罗非昔布的纯化形式、制备方法和用途
EP3930713B1 (de) 2018-12-04 2025-05-28 Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi Stabile tacrolimus-salbenformulierung zur topischen behandlung von hauterkrankungen
AU2020234718A1 (en) 2019-03-13 2023-05-18 Tearsolutions, Inc. Compositions and methods for promoting islet viability and enhancing insulin secretion
US12447119B2 (en) 2019-03-18 2025-10-21 Sunstar Americas, Inc. Oral care composition
GR1009790B (el) * 2019-03-20 2020-08-03 Φαρματεν Α.Β.Ε.Ε. Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους
US10752642B1 (en) 2019-04-30 2020-08-25 George Mason University Macrocyclic lactones
EP3861989A1 (de) * 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmazeutische zusammensetzung mit regorafenib und stabilisierungsmittel
US11666560B2 (en) 2020-09-24 2023-06-06 George Mason University Anti-fibrotic agent
CN117177749A (zh) 2021-03-03 2023-12-05 萨那生物科技公司 与心肌细胞疗法一起使用的免疫抑制疗法以及相关的方法和组合物
CN117241786A (zh) * 2021-03-12 2023-12-15 德克萨斯大学系统董事会 使用基于悬浮液的薄膜冷冻制备干燥粉末的方法
CN114469847B (zh) * 2021-12-29 2024-08-13 北京鑫开元医药科技有限公司 他克莫司栓剂及其制备方法和用途
CN116159034B (zh) * 2023-04-23 2023-07-04 国药集团川抗制药有限公司 一种他克莫司缓释胶囊及其制备方法
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925231A (ja) 1983-07-11 1984-02-09 Hitachi Ltd シリコンウエ−ハ
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
JPH0650393B2 (ja) 1985-07-30 1994-06-29 日本合成ゴム株式会社 ポジ型放射線感応性組成物
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
KR0177158B1 (ko) 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5601844A (en) 1992-11-18 1997-02-11 Fujisawa Pharmaceutical Co., Ltd. Sustained release medicinal preparation
JPH06227732A (ja) 1993-02-02 1994-08-16 Sharp Corp 複写機におけるシート後処理装置
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
US6239124B1 (en) * 1996-07-30 2001-05-29 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
ZA9710927B (en) 1996-12-06 1998-06-15 Fujisawa Pharmaceutical Co Pharmaceutical composition.
TW450810B (en) 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
US6440458B1 (en) * 1998-03-26 2002-08-27 Fujisawa Pharmaceutical Co., Ltd. Sustained release preparations
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6168806B1 (en) * 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
JP3405261B2 (ja) 1999-03-30 2003-05-12 トヨタ自動車株式会社 筒内噴射式火花点火内燃機関
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007842D0 (en) 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US20020028240A1 (en) 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
EP1275373A4 (de) 2000-04-17 2007-04-04 Astellas Pharma Inc Arzneistoffabgabesystem zur vermeidung von pharmakokinetischen wechselwirkungen zwischen wirkstoffen und methode hierzu
JP2004503511A (ja) 2000-06-12 2004-02-05 スミスクライン・ビーチャム・コーポレイション 新規固体分散剤組成物
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
RU2330642C2 (ru) 2001-07-06 2008-08-10 Лайфсайкл Фарма А/С Регулируемая агломерация
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2005004848A1 (en) 2003-07-09 2005-01-20 Chong Kun Dang Pharmaceutical Corp. The solid dispersion of tacrolimus
BRPI0413927B8 (pt) 2003-08-29 2021-05-25 Lifecycle Pharma As composição farmacêutica compreendendo tacrolimus, forma de dosagem, uso da composição, e, método para a preparação da composição
SI1663217T1 (sl) * 2003-08-29 2010-10-29 Lifecycle Pharma As Trdne disperzije, ki vsebujejo takrolimus
EP1675576A1 (de) 2003-10-03 2006-07-05 LifeCycle Pharma A/S Verfahren zur herstellung von pharmazeutischen zusammensetzungen mit modifizierter freisetzung
NO320286B1 (no) 2003-11-19 2005-11-21 Dag Herman Zeiner-Gundersen Turbin for kraftproduksjon
AU2005219443A1 (en) 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
AU2005316473B2 (en) 2004-12-15 2011-07-14 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
CN101175481A (zh) 2005-03-17 2008-05-07 伊兰制药国际有限公司 纳米颗粒免疫抑制化合物的可注射的组合物
ES2634153T3 (es) 2007-05-30 2017-09-26 Veloxis Pharmaceuticals A/S Forma de dosificación oral de una vez al día que comprende tacrolimus
US8383135B2 (en) 2010-12-03 2013-02-26 Richard C. Fuisz Solid dosage form that promotes reliable oral, esophageal and GI transit

Also Published As

Publication number Publication date
US20160166551A1 (en) 2016-06-16
AU2004267910B2 (en) 2011-01-06
JP2007504102A (ja) 2007-03-01
WO2005020994A1 (en) 2005-03-10
US10548880B2 (en) 2020-02-04
US11077096B2 (en) 2021-08-03
US8617599B2 (en) 2013-12-31
US9763920B2 (en) 2017-09-19
US20200289478A1 (en) 2020-09-17
PL1663217T3 (pl) 2010-12-31
NO337869B1 (no) 2016-07-04
US20140065225A1 (en) 2014-03-06
JP4996249B2 (ja) 2012-08-08
US20110250277A1 (en) 2011-10-13
US20100008984A1 (en) 2010-01-14
US8889186B2 (en) 2014-11-18
CA2537044C (en) 2012-04-17
CA2537041A1 (en) 2005-03-10
US20110263632A1 (en) 2011-10-27
PL1663216T3 (pl) 2012-03-30
DE602004028023D1 (de) 2010-08-19
CA2537041C (en) 2012-04-03
AU2004267909B2 (en) 2008-12-18
HK1096032A1 (en) 2007-05-25
US8889185B2 (en) 2014-11-18
US20110251231A1 (en) 2011-10-13
US20130189318A1 (en) 2013-07-25
US9161907B2 (en) 2015-10-20
US9757362B2 (en) 2017-09-12
US20180228779A1 (en) 2018-08-16
US7994214B2 (en) 2011-08-09
BRPI0414000A (pt) 2006-10-24
US20110256190A1 (en) 2011-10-20
BRPI0414000B8 (pt) 2021-05-25
NO20061429L (no) 2006-05-29
BRPI0413927A (pt) 2006-10-24
US20140066473A1 (en) 2014-03-06
BRPI0413927B1 (pt) 2019-11-12
NO20061430L (no) 2006-05-29
US20160243090A1 (en) 2016-08-25
US11129815B2 (en) 2021-09-28
JP2011251972A (ja) 2011-12-15
US8486993B2 (en) 2013-07-16
US8586084B2 (en) 2013-11-19
BRPI0413927B8 (pt) 2021-05-25
US20140073665A1 (en) 2014-03-13
US8623411B2 (en) 2014-01-07
EP1663217A1 (de) 2006-06-07
EP1663216B1 (de) 2011-11-02
AU2004267909A1 (en) 2005-03-10
NO334986B1 (no) 2014-08-18
WO2005020993A1 (en) 2005-03-10
EP1663217B1 (de) 2010-07-07
US20110251232A1 (en) 2011-10-13
US8623410B2 (en) 2014-01-07
EP1663216A1 (de) 2006-06-07
CA2537044A1 (en) 2005-03-10
AU2004267910A1 (en) 2005-03-10
US20180214422A1 (en) 2018-08-02
BRPI0414000B1 (pt) 2019-11-05

Similar Documents

Publication Publication Date Title
ATE473003T1 (de) Tacrolimus enthaltende feste dispersionen
WO2006108075A3 (en) Compositions and methods for enhancing drug sensitivity and treating drug resistant infections an diseases
AP2507A (en) Quinoline derivatives and use thereof as mycobacterial inhibitors.
IL198687A0 (en) Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
DK1663217T3 (da) Faste dispersioner indeholdende tacrolimus
WO2005065241A3 (en) Smmr (small molecule metabolite reporters) for use as in vivo glucose biosensors
CA2528162A1 (en) Pni microarray and uses
TW200621238A (en) Pharmaceutical formulation
WO2006042138A8 (en) Systems and methods for ex-vivo organ care
WO2007067782A3 (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
EA201200934A1 (ru) Противораковые комбинации лекарственных средств на основе артемизинина с другими химиотерапевтическими агентами
WO2008033987A3 (en) Compositions and methods to prevent cancer with cupredoxins
WO2007070640A3 (en) Use of roma for characterizing genomic rearrangements
WO2005041747A3 (en) Stealthy nano agents
ATE434639T1 (de) Wässrige dispersionen von silikon-polyether- blockcopolymeren
WO2008081829A1 (ja) 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
WO2009026257A3 (en) Methods and compositions for controlling the bioavailability of poorly soluble drugs
WO2005097195A3 (en) Methods of reducing aggregation of il-1ra
WO2006097617A3 (fr) Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
NO20076120L (no) Stabile nanopartikkelformuleringer
IL175665A0 (en) Pharmaceutical compositions and kits containing an antineoplastic thiol-binding mitochondrial oxidant and an antineoplastic nucleic acid binding agent
DE602005018840D1 (de) 3'-modifizierte oligonukleotide mit pseudoisocytosin-nukleobasenderivaten sowie deren anwendungen als primer oder sonden
WO2005035549A3 (en) Amiphiphylic peptide-pna conjugates for the delivery of pna through the blood brain barrier
WO2006091847A3 (en) Clopidogrel base suitable for pharmaceutical formulation and preparation thereof
GEP20074183B (en) Indazole having analgesic activity

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1663217

Country of ref document: EP